The latest early trial data suggests that current daily HIV pill regimens could potentially be replaced with injections that slowly release medication for the virus over time. This new method has proven to be as successful as current treatment plans and could provide the same benefits in just six injections annually. Antiretroviral treatment suppresses the
Genmab and their partner Johnson & Johnson have today announced positive mid-stage clinical data on daratumumab for multiple myeloma. The preliminary results are from a 124-patient Phase II client trial of daratumumab in double refractory multiple myeloma conducted by J&J’s Janssen Biotech unit. The results show an overall response rate of 29.2% in the 16
Johnson & Johnson and Vectura have announced a new partnership to develop anti-inflammatory therapies for asthma and chronic obstructive pulmonary disease (COPD). Vectura, who are respiratory specialists, confirmed that the collaboration will primarily focus on a Phase II treatment, but may also include additional clinical-stage candidates.
GlaxoSmithKline and Johnson & Johnson (J&J) announced yesterday that they have started Phase III clinical trials of their investigational rheumatoid arthritis (RA) treatment, sirukumab. Johnson & Johnson’s Janssen Biologics unit in Ireland and GlaxoSmithKline have begun a Phase III development programme for sirukumab (otherwise known as CNTO 136), a human anti-interleukin (IL)-6 monoclonal antibody. The
Johnson & Johnson’s Janssen Research & Development unit yesterday announced that they have filed a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for bedaquiline, in the hope that it will be the first drug with a new mechanism of action for tuberculosis (TB) in over 40 years. Specifically, Janssen is
Janssen Research & Development announced earlier this week that they have submitted supplemental New Drug Applications (sNDAs) to the US FDA (Food and Drug Administration). Janssen are pursuing approval from the FDA for the use of XARELTO (rivaroxaban), an oral anticoagulant, to treat patients with deep vein thrombosis (DVT) or pulmonary embolism (PE) and prevention
The UK’s National Institute for Health and Clinical Excellence (NICE) has issued final draft guidance recommending Janssen Cilag’s Incivo (telaprevir), in combination with Roche’s peginterferon alfa and ribavirin, as an option for the treatment of genotype 1 chronic hepatitis C in adults with compensated liver disease. The final draft guidance recommends the drug as an
Sweden’s Orexo suffered a major setback yesterday after the announcement that Johnson & Johnson had decided to end the firms’ anti-inflammatory collaboration. The agreement with the healthcare company’s Janssen Pharmaceuticals unit aligned around two research projects in the arachidonic acid field. The OX-CLI and OX‑ESI programmes were concentrated on developing treatments for asthma, chronic obstructive